These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8595506)

  • 41. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs.
    Schooley RT
    AIDS; 1995 Dec; 9 Suppl 2():S15-S19. PubMed ID: 8775802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ACTG 152: new insights into pediatric antiretroviral therapy.
    Bowersox J
    NIAID AIDS Agenda; 1996 Mar; ():3. PubMed ID: 11363798
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapid screening of antiretroviral combinations.
    St Clair M; Pennington KN; Rooney J; Barry DW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S24-7. PubMed ID: 8595504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction.
    Aoki-Sei S; Yarchoan R; Kageyama S; Hoekzema DT; Pluda JM; Wyvill KM; Broder S; Mitsuya H
    AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1263-70. PubMed ID: 1520538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV-1 burden as a marker of disease progression and clinical response to therapy in AIDS.
    Coombs RW
    Clin Lab Med; 1994 Jun; 14(2):301-11. PubMed ID: 7924193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative analysis of genetic toxicity of antiretroviral combinations in somatic cells of Drosophila melanogaster.
    Guimarães NN; Silva CJ; de Andrade HH; Dihl RR; Lehmann M; Cunha KS
    Food Chem Toxicol; 2013 Mar; 53():299-309. PubMed ID: 23261680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CPCRA 007: preliminary results of combination antiretroviral study.
    Randall P
    NIAID AIDS Agenda; 1996 Mar; ():2. PubMed ID: 11363796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Antiretroviral treatments in human immunodeficiency virus infection].
    Dormont J; Aboulker JP
    Rev Prat; 1994 Jun; 44(12):1635-42. PubMed ID: 7939239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early treatment of HIV infection.
    Fessel WJ
    N Engl J Med; 1995 Dec; 333(26):1782; author reply 1783. PubMed ID: 7491153
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of resistance on combination chemotherapy for human immunodeficiency virus infection.
    Cox SW; Albert J; Ljungdahl-Ståhle E; Wahren B
    Adv Enzyme Regul; 1993; 33():27-36. PubMed ID: 7689290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring the activity of antiviral therapy for HIV infection using a polymerase chain reaction method coupled with reverse transcription.
    Kojima E; Shirasaka T; Anderson B; Chokekijchai S; Sei S; Yarchoan R; Mitsuya H
    AIDS; 1993 Nov; 7 Suppl 2():S101-5. PubMed ID: 8161438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment modalities for patients with HIV disease.
    Molaghan JB
    J Intraven Nurs; 1991; 14(3 Suppl P):S25-9. PubMed ID: 2033484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of potentially interfering substances on the measurement of HIV-1 viral load by the bDNA assay.
    Alonso R; García de Viedma D; Rodríguez-Creixems M; Bouza E
    J Virol Methods; 1999 Mar; 78(1-2):149-52. PubMed ID: 10204704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.
    Cohen OJ; Pantaleo G; Holodniy M; Schnittman S; Niu M; Graziosi C; Pavlakis GN; Lalezari J; Bartlett JA; Steigbigel RT
    Proc Natl Acad Sci U S A; 1995 Jun; 92(13):6017-21. PubMed ID: 7597072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transient dissociation between infectious HIV-1 titer and viral RNA during the early phase of AZT treatment.
    Zöllner B; Stellbrink HJ; Feucht HH; Schröter M; Baumgartner EM; Laufs R
    Microbiol Immunol; 1998; 42(6):471-3. PubMed ID: 9688082
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiretroviral treatment progress reports from a European conference.
    Chang HE
    BETA; 1995 Dec; ():10-2. PubMed ID: 11363003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds.
    Bagnarelli P; Menzo S; Valenza A; Paolucci S; Petroni S; Scalise G; Sampaolesi R; Manzin A; Varaldo PE; Clementi M
    J Clin Microbiol; 1995 Jan; 33(1):16-23. PubMed ID: 7699034
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New technologies for quantifying HIV: amplification assays directly measure the virus at all stages of infection.
    J Int Assoc Physicians AIDS Care; 1995 Nov; 1(10):14-5. PubMed ID: 11362970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination therapy: more effective control of HIV type 1?
    Johnson VA
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):907-12. PubMed ID: 7811541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia.
    Bush CE; Donovan RM; Markowitz N; Baxa D; Kvale P; Saravolatz LD
    J Clin Microbiol; 1996 Apr; 34(4):970-2. PubMed ID: 8815119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.